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ABSTRACT
INVESTIGATING THE EFFECTS OF PERFLUOROOCTANOIC SULFONATE
(PFOS) AND ETHANOL ON FATTY LIVER DISEASE USING A MODIFIED
NIAAA MODEL
Tyler Charles Gripshover
May 20, 2021
Perfluoroalkyl Substances (PFAS) are a family of man-made, surfactant-like
compounds that are a major environmental contaminant. A multitude of studies
have indicated that PFAS are able to induce fatty liver disease and modulate lipid
metabolism. However, the distinct mechanism of PFAS influence on the liver and
metabolism disruption remains to be elucidated. On the other hand, it is well
documented that alcohol consumption has various adverse health impacts
including fatty liver disease and subsequent progression to more adverse liver
states. To date, there are no published studies on whether PFAS and alcohol can
jointly exacerbate fatty liver progression or interact to disturb lipid metabolism. It
is hypothesized that PFOS and alcohol will interact to exacerbate fatty liver but
co-independently modulate metabolism. This study seeks to characterize the
phenotype after male C57BL/6 mice are exposed to Perfluorooctanoic Sulfonate
(PFOS), a prominent PFAS, while ad libitum consuming an alcohol diet.
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CHAPTER I
INTRODUCTION
Fatty Liver Disease (FLD)
Fatty liver diseases are a growing global health concern and have multiple
etiologies reflected by alcohol consumption (alcoholic liver disease), diet and
obesity (non-alcoholic fatty liver disease), and toxicant exposure (toxicantassociated fatty liver disease). These disease subsets are generally
characterized by dyslipidemia and excess triglyceride accumulation in
hepatocytes that may be accompanied with developing inflammation and fibrosis
(1). Pathological FLD progression exists on a spectrum from simple hepatic
steatosis to more advanced states comprised of steatohepatitis, cirrhosis, and
hepatocellular carcinoma (HCC). Reviewed further by Toshikuni, N. et al,
alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are
similar in pathology but have distinct clinical outcomes (2).
Alcohol use prevalence is rising which is followed by increased preventable
deaths, hospitalizations, and healthcare costs (3). According to the National
Institute of Alcohol Abuse and Alcoholism (NIAAA), among adults over the age of
18, it is estimated that 85.6% of people have drank at some point in their life and
54.9% of people reported that they drank within the past month (4, 5). Alcohol
consumption alone cause half of the deaths attributed to chronic liver diseases
1

and studies have reported that ALD inpatient hospital admissions have a greater
median total cost than other chronic liver disease patients (6, 7). Alcohol toxicity
affects all major organs, but it is known that alcoholic liver disease is the major
lethal outcome from chronic alcohol use (6).
It is estimated that at least 25% of the global adult population has NAFLD which
is often associated with other metabolic comorbidities such as obesity, type-II
diabetes, and cardiovascular diseases (8). Between 2012 and 2016, there was a
20.8% increase in chronic liver disease-related hospitalizations and in 2016,
hospitalizations accounted for $18.8 billion healthcare costs (9). The two ‘hit’
hypothesis has been proposed to describe how some individuals with NAFLD
progress more quickly towards more severe or chronic FLD states (10, 11). In
some instances, oxidative stress, inflammation, mitochondrial dysfunction, and
an altered microbiome may act as the second ‘hit’ to advance simple fatty liver to
developing fibrosis or cirrhosis. It is becoming increasingly evident that toxicant
exposure may also contribute as a second ‘hit’ to worsen hepatic prognosis (12).
Previously, our laboratory has associated toxicant exposure and increased
NAFLD severity in The National Health and Nutrition Examination Study
(NHANES) (13). Further research led our laboratory to associate and
characterize various environmental pollutant’s ability to progress FLD to more
severe states and coined the term ‘toxicant-associated steatohepatitis’ (TASH)
(14). Toxicant-associated fatty liver disease (TAFLD) is a more recently
described term that has been proposed to classify fatty liver pathology distinct
from ALD and NAFLD (15). TAFLD is proposed as consequential fatty liver
2

following xenobiotic exposure that disrupts energy metabolism and promotes
hepatic injury and subsequent inflammation. A global prevalence and total cost
estimate of TAFLD is difficult to assess because of the high abundance and
diversity of environmental pollutants that cause metabolic syndrome or FLD.
Most epidemiology studies tend to focus on a single pollutant or class of
pollutants that report specific etiologies or healthcare costs, implicating that the
total TAFLD burden to human liver health remains unknown.
Perfluoroalkyl substances (PFAS)
Perfluoroalkyl substances are synthetic, surfactant-like compounds that have
been in production since the 1940’s (16). PFAS are widely used in industry and
consumer products such as clothing, food packaging materials, carpets and
upholstery, cookware, and others. They are a large family consisting of at least
4,700 known congeners (17). See Figure 1 for structures of two widely known
and studied PFAS congeners (18). PFAS are useful due to their amphipathic
chemical nature and contain strong carbon-fluorine bonds that make them
resistant to thermal, acid-base, and oxidative digestion. Due to their fluorinated
carbon back bone, PFAS compounds have long half-lives and tend to
bioaccumulate in biological systems. For instance, perfluorooctane sulfonate
(PFOS), perfluorooctanoic acid (PFOA), and perfluorohexane sulfonate (PFHxS),
frequently detected PFAS congeners in human blood, have mean half-lives of
3.4, 2.7, and 5.3 years, respectively (19). It should come as no surprise that
PFAS compounds are detectable in at least 98% of Americans and are
considered persistent organic pollutants (POPs) (20).
3

Major routes of human exposure to PFAS consist of ingestion of contaminated
drinking water and food products (21). PFAS manufacturing companies such as
3M, have been voluntarily phasing out legacy compounds (i.e., PFOS, PFOA,
PFHxS) since the early 2000’s (22). Although legacy PFAS levels are declining,
they are still being detected in the environment and in human blood almost 20
years later (21-23). Despite these efforts, government restrictions on the
manufacture and use of these compounds are limited to the Environmental
Protection Agency’s (EPA) lifetime health advisory warning of 70 parts per trillion
(ppt) (24).
In general, PFAS have been associated with a range of adverse health effects
including hepatic steatosis, dyslipidemia, hypercholesterolemia, endocrine and
metabolism disruption, decreased response to vaccines, and increased risk for
some cancers (25-27). Of interest, PFAS have shown to activate multiple nuclear
receptors and their respective pathways to disturb energy metabolism (28, 29).
Some of the most consistent data collected in PFAS research is the activation of
peroxisomal proliferator activated receptor alpha (PPARα) and subsequent
disruption of lipid homeostasis pathways. However, it should be noted that there
are distinct differences in human and mouse PPARα activity, expression, and
ligand specificity resulting in unique outcomes (30, 31). This phenomenon is
leading more investigators to use humanized-PPARα (hPPARα) or PPARαknockout models to discriminate possible species differences and PPARαindependent effects (29, 32). Species differences warrant further investigation for
PFAS compounds and their unique impact on human and mouse metabolism.
4
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Alcohol Consumption and Related Health Effects
Alcohol consumption has become a staple in industrialized countries like the
United States and various European countries (33). As defined by the NIAAA,
there are standard drinks for males and females and various drinking patterns
that are observed in the general population. A standard drink in the United States
is defined as one with 14 grams or 0.6 fluid ounces of pure alcohol (34). Low risk
drinking behavior is defined for females as no more than three drinks a day and
no more than seven in a week. Alternatively, no more than four drinks a day and
no more than fourteen drinks in a week for men (35). Besides low-risk or
moderate drinking, consumption patterns have been characterized from bingeing
or extreme bingeing, to chronic or heavy drinking (35). Each of these drinking
patterns can have a negative impact on health if drinking chronically persists or if
individuals have pre-existing health issues that worsen alcohol-related outcomes
(36).
It is well characterized that alcohol affects the liver, central nervous system,
cardiovascular system, and the gut microbiome (37-39). Much of the ongoing
alcohol research uses the NIAAA ten-plus-one model to investigate alcohol
effects (40). Of interest, the liver is a primary target due to its role in metabolizing
roughly 90% of ingested alcohol by alcohol dehydrogenase (ADH) and
cytochrome P450, Cyp2e1 (41). It is known that alcohol consumption promotes
hepatic inflammation while modulating lipid metabolism (42). This then induces
steatosis which may progress to steatohepatitis and cirrhosis (42, 43). To
reiterate, ALD is similar to NAFLD in terms of pathology, but differ in etiology.
6

This makes studying the two diseases challenging as they are phenotypically
similar, but injury and metabolic outcomes can sometimes vary considerably.
Alcohol-related hepatoxicity also results from mitochondrial damage from
reactive oxygen species (ROS) generation and impaired lipid peroxidation (39,
44). Chronic alcohol consumption can promote hepatic steatosis by altering
PPARα, sterol‐regulatory element binding protein‐1 (Srebp‐1), and liver X

receptor‐α (LXRα) expression (45-47). Expression alteration of these genes
surmounts to impacted energy metabolism and culminate as metabolic disorders
that may be comorbid with other alcohol-related insults.
Significance of Study
As a lifestyle factor, alcohol consumption has been a major consideration in
epidemiology studies due to its ability to confound results. Largely, alcohol
effects are being investigated independently of other environmental pollutants.
There is a longstanding gap in the literature that investigates how environmental
pollutants, like PFAS, modulate alcohol-related pathology. Generally, alcohol and
toxicants associated with fatty liver disease have similar mechanisms of insult
including mitochondrial dysfunction, disrupted lipid metabolism, altered cytokine
levels, and nuclear receptor activation (14, 42, 48). Our group has previously
shown that diet, another lifestyle factor, and environmental pollutants can interact
to worsen fatty liver disease (14, 49, 50). It is hypothesized that alcohol use and
toxicant exposure may interact to modulate metabolic pathways involved in liver
disease. Unfortunately, there have been few alcohol models that include toxicant
co-exposure. There is a need for an alcohol-plus-toxicant model to characterize
7

the phenotype and mechanism of action in co-exposed biological systems. Here,
we describe a pilot study aimed to characterize the phenotype after mice are
exposed to PFOS while ad libitum consuming an alcohol diet. We hypothesize
that PFOS will modulate alcohol-induced steatosis and lipid and cholesterol
metabolism.
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CHAPTER II
MATERIALS AND METHODS
Animal Procedures and Diets
The animal protocol and procedures were approved by the University of
Louisville Institutional Animal Care and Use Committee. Forty, ten-week-old
C57BL/6 male mice were purchased from Jackson Laboratory (Bar Harbor,
Maine). Upon arrival, mice were housed in a temperature-controlled room
(23.9°C) with a 12-hour light-dark cycle in a specific pathogen-free animal facility
accredited by the Association for Assessment and Accreditation of Laboratory
Animal Care (AAALAC). Mice were allowed to acclimate to facility transfer for
one week and maintained on autoclaved laboratory rodent chow diet (5010;
LabDiet, St. Louis, Missouri) and had ad libitum access to food and water. A
chronic-binge experimental animal model of ALD was used as a foundational
model for the duration of the study (40).
Mice were divided into four groups: pair-fed+vehicle, pair-fed+PFOS, ethanolfed+vehicle, and ethanol-fed+PFOS. Each cage was fitted with two, 50 mL liquid
diet feeders (cat: 9019; Bio-Serv; Flemington, New Jersey). Ethanol-fed cages
were always supplemented with 100 mL diet, whereas the pair-fed cages were
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provided control (maltose dextrin) diet volume equivalent to the amount of
ethanol diet consumed the day prior. Alcohol-fed mice acclimated to the Rodent
Liquid Lieber-DeCarli '82, Shake and Pour (Bio-Serv; Flemington, New Jersey)
alcohol diet by incrementally increasing percent ethanol from 0% to 5% (v/v) (cat:
F1258SP) over the course of one week. Ethanol-fed mice were maintained on
the 5% ethanol diet for the remaining fifteen days of the study. Control mice are
deemed ‘pair-fed’ to ensure mice between groups are kept isocaloric with
supplemented maltose dextrin in place of ethanol. Pair-fed mice were acclimated
the same time as ethanol-fed mice, but were maintained on the control, maltose
dextrin diet (cat: F1259SP) for the remainder of the study. After six days of diet
acclimation, ethanol-fed mice were then fed a final concentration of 5% ethanol
supplemented with the diet for fifteen days. Pair-fed mice were maintained on the
0% ethanol, maltose dextrin diet for fifteen days after acclimation. Mice were
weighed weekly during facility transfer, diet acclimation, and the first five days of
5% ethanol feeding. For the remainder of the study, mice were weighed and
scored daily for health assessment and to calculate the dose of PFOS needed for
each mouse via oral gavage. Body condition scoring ranged from a score of 1,
indicating that the mouse is emaciated, to 5, indicating the mouse is obese. This
evaluation is done by gently holding the mouse by the base of the tail and
passing a finger over the sacroiliac bones. Mice demonstrating evident distress
by >20% weight loss, poor grooming, and/or hunched posture, it will be humanely
euthanized according to our Institutional Animal Care and Use Committee
(IACUC) protocol.
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Animal Exposures
Beginning six days after 5% ethanol feeding started, mice were orally gavaged
with vehicle (2% USP Tween-80 solution; cat: 1547969; MilliporeSigma) or
1mg/kg body weight Heptadecafluorooctanesulfonic acid potassium salt (PFOSK+) (cat: 77282-10G; Sigma Aldrich) daily for the duration of the study. This dose
was chosen to explore lower exposures and recapitulate no observed adverse
effect level in previous studies (51-53). Total exposure to PFOS is estimated to
be 10 mg/kg, as mice were orally gavaged 1 mg/kg for the last ten days of study.
On the final day nine hours pre-euthanasia and tissue collection, mice were orally
gavaged 5 g/kg ethanol (binge) or facility water. At euthanasia, mice were
anesthetized with Ketamine:Xylazine (120:16 mg/kg) via intraperitoneal injection.
This anesthesia method is then followed by exsanguination and subsequent
blood and tissue harvesting. Blood was collected with 0.2 molar
ethylenediaminetetraacetic acid (cat: E6511-500G; Sigma Aldrich) and
centrifuged for plasma collection. Plasma was stored at −80°C and tissue
samples were either snap frozen in liquid nitrogen or fixed in 10% neutralbuffered formalin for histological analysis.
Liver Histology
Liver tissues were fixed in 10% neutral buffered formalin and then paraffin
embedded for histological examination. Liver tissues were sectioned at 5 μm with
Leica Biosystem’s Histocore Autocut Automated Rotary Microtome (Leica
Biosystem, Wetzlar, Germany). Liver morphology was visualized with
hematoxylin and eosin (H&E) staining (Modified Mayers Hematoxylin, Sigma
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Aldrich Eosin). Images were captured at 20x using an Olympus BX43
microscope, DP74 digital camera, and CellSens Software package (Olympus
America, Breinigsville, PA, USA) courtesy of Dr. Irina Kirpich’s laboratory.
RT-PCR
Liver tissues were processed for chloroform-methanol RNA isolation method
using RNA-STAT60 (cat: CS-502; Tel-test inc.). cDNA synthesis was performed
using cDNA Synthesis Kit (Quantabio, Beverly, Massachusetts). RT-PCR was
performed on the CFX384 TM Real-Time System (BioRad; Hercules, California)
using iTaq Universal Probes Supermix and Taqman probes purchased from
ThermoFisher Scientific (Appendix I). Gene expression levels were calculated
using the 2-ΔΔCt method. mRNA levels were normalized relative to housekeeping
gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH; cat: 4352339E;
ThermoFisher Scientific) and mean expression levels in pair-fed+vehicle mice.
Biochemical Analyses
Plasma aspartate aminotransferase (AST), alanine aminotransferase (ALT), total
cholesterol, triglycerides, lipoproteins (HDL, LDL, VLDL), and glucose were
measured with the Piccolo Xpress Chemistry Analyzer using Lipid Panel Plus
diskettes (PN: 400-0030; Abaxis). This blood chemistry analysis was performed
as recommended by the manufacturers protocol. Plasma adipokines and
cytokines were measured using the Milliplex Map Mouse Adipokine Magnetic
Bead Panels (cat: MADKMAG-71K; EMD Millipore) on a Luminex 100 system
(Luminex Corp, Austin, Texas). Plasma adipokines and cytokines measured
12

were Interleukin-6 (IL-6), Insulin, Leptin, Monocyte chemoattractant protein-1
(MCP-1), Plasminogen activator inhibitor-1 (PAI-1), Resistin, and Tumor necrosis
factor-alpha (TNFα). This assay was performed based on manufacturer’s
recommended protocol. Hepatic triglycerides and cholesterol content were
extracted according to the Bligh and Dyer method using a chloroform and
methanol (2:1) solution (54). Triglycerides and cholesterol standards were
measured using Infinity Liquid Stable Reagents (cat: T7531-STD, C7509-STD;
Point Scientific) and were used according to the manufacturers protocol. Hepatic
triglycerides and cholesterol were colorimetrically measured on a microplate
absorbance reader (BioTek Gen 5, Winsooki, Vermont).
Statistical Analysis
Statistical analyses and graphs were plotted using GraphPad Prism (ver.
9.1.0.221.) for Windows (GraphPad Software, Inc, La Jolla, California). All data
are described as mean ± SD. Statistical analyses were performed on GraphPad
Prism software using the two-way Analysis of Variance (ANOVA) for two factors:
“diet” and “exposure” unless indicated otherwise. This analysis was then followed
by multiple comparisons using Tukey’s post hoc test where p<0.05 was deemed
statistically significant. Significance was displayed above figures as ‘a’ for diet, ‘b’
for PFOS, and ‘c’ for interaction effect(s).
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CHAPTER III
RESULTS
Phenotypic Characterization: Body Composition & Diet Consumption
It is known that mice do not typically respond positively to the addition of alcohol
in diet and may exhibit weight loss. C57BL/6 mice are known to lose weight, but
adjust to alcohol diets more easily without exhibiting severe weight loss and do
not exhibit severe hepatic response to ethanol consumption compared to other
strains (40). Exposure group body weights and diet consumption were recorded
and are displayed in Figure 2. Each exposure group consisted of ten, ten-weekold male C57BL/6 mice and approximately weighed 27 grams during the initial
weight recording. Mice steadily gained weight when initially exposed to the
Lieber-DeCarli diet. However, as alcohol concentration increased up to 5%
ethanol, all animals exhibited weight loss. Exposure groups proceeded to lose
weight until day 15 for pair-fed mice and day 19 for ethanol-fed mice. We
hypothesize that this occurrence was due to the synonymous stress of daily oral
gavage where the co-exposure groups displayed a prolonged decrease of body
weight. Future exposure parameters will be adjusted by performing biweekly oral
gavage rather than daily so that weight loss is minimized. Mouse body conditions
were monitored each day and recorded (not shown). Body conditions ranged
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between 2-3 for all mice indicating that most mice were healthy or exhibited
minor weight loss throughout the study. This is supported by body weight records
shown in Figure 2.
Diet consumption was measured daily to ensure adequate intake and to keep the
pair-fed group isocaloric to the ethanol-fed mice. During the diet acclimatization
period and upon 5% ethanol addition, diet intake decreased steadily until about
day 12. After day 12, diet consumption moderately increased or stabilized for the
remainder of the study. Diet intake fluctuation was expected as it takes time for
mice to adjust to the liquid diets. Future study design may incorporate additional
food so that pair-fed mice are not limited in diet intake so they do not experience
severe weight loss.

15
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Hepatic Characterization: Impact of PFOS Exposure and Alcohol
Consumption on Steatosis and Injury
This acute, pilot study ultimately aimed to characterize the phenotype after mice
are exposed to PFOS while consuming an alcohol diet. Fatty liver is an expected
outcome in this study and was investigated based on liver-to-body weight ratio
and H&E staining of hepatocyte morphology and lipid droplet formation. Liver-tobody weight ratio can be seen in Figure 3 depicting increased liver weights in the
ethanol-fed mice. Interestingly, liver weights were further increased in mice
consuming an alcohol diet and exposed to PFOS; however, a PFOS exposure
did not affect liver weight in the pair-fed exposure groups.

17
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H&E staining was performed to determine changes in hepatocyte morphology
and to image lipid droplet accumulation and pattern formation. Representative
sections of each exposure group are displayed in Figure 4. H&E staining
indicated histological steatosis and lipid droplet accumulation in the PFOS and
ethanol-fed groups. PFOS exposure in pair-fed mice exhibited slight
accumulation of lipid droplet formation. The ethanol-fed+vehicle group exhibited
some macrosteatosis that is typically observed in the Lieber-DeCarli alcohol diet
(40, 55). Finally, the ethanol-fed+PFOS co-exposure group displayed marked
lipid droplet accumulation and macrosteatosis. Other histological observations in
the co-exposure group included slight vasculature disruption, some ballooning of
hepatocytes, and some leukocyte infiltrates. Future studies will incorporate
specific leukocyte histological stains such as Choleracetate Esterase stain for
neutrophils or F4/80 stain for monocytes/macrophages.

19
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Finally, total hepatic triglycerides and cholesterol were isolated using the Bligh
and Dyer method and were quantified using a spectrophotometer. Total hepatic
triglycerides and cholesterol are displayed as mg/g of liver in Figure 5. Hepatic
triglycerides and cholesterol reflect a dominate alcohol effect where hepatic
triglycerides are elevated and hepatic cholesterol was decreased in the ethanolfed mice. There was a trending increase in hepatic triglycerides and a trending
decrease in hepatic cholesterol, however these observations were not
statistically significant. An increase in hepatic triglycerides were expected as
ethanol and PFOS exposure tend to result in lipid accumulation in the liver (25,
56, 57). A decrease in cholesterol due to PFOS exposure was expected and is a
unique observation in rodents relative to human epidemiological studies (58, 59).

21

22

We next characterized ethanol’s known injurious impact on the liver in
conjunction with PFOS exposure for this model. Liver injury is often determined
in the clinic and laboratory by assessing the levels of plasma alanine
aminotransferase (ALT) and aspartate aminotransferase (AST). These two
enzymes are critical in amino acid metabolism to generate substrates for protein
synthesis and the citric acid cycle (60). ALT and AST are useful liver injury
biomarkers because their elevated presence in plasma indicate hepatocellular
distress. Mean ALT and AST levels are displayed in Figure 6 for each exposure
group. Both ALT and AST levels were significantly elevated in the ethanol
exposed group as expected due to fifteen days of 5% ethanol consumption and a
single oral gavage bolus of 5 g/kg ethanol nine hours prior to euthanasia. PFOS
exposure however did not influence ALT and AST levels in this model.
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Previous studies have demonstrated that upon ethanol consumption, proinflammatory cytokines are released as a consequence of ethanol’s presence
and its conversion to acetaldehyde (42, 61, 62). On the other hand, studies
investigating immune effects of PFAS have shown to be contradictory and have
shown pro- and anti-inflammatory effects (26, 56, 63, 64). Figure 7 displays gene
expression and plasma protein levels of IL-6. Gene expression of IL-6 showed an
interaction effect in the co-exposed group, while plasma assessment of IL-6
cytokine was shown to be increased due to ethanol consumption only. Other
cytokines such as TNF-α, C-C Motif Chemokine Ligand’s 2, 3, 8 (CCL2, CCL3,
CCL8), Interleukin-1β (IL-1β), and Transforming Growth Factor-beta (TGF-β)
expression and protein levels were assessed by either RT-PCR or Luminex but
were not significantly different relative to pair-fed+vehicle control (not shown).
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Disruption of Energy and Xenobiotic Metabolism
Previous studies have indicated that PFAS compounds disrupts lipid
homeostasis to induce fatty liver disease (25, 26, 29). Likewise, alcohol
consumption also induces fatty liver and other comorbid conditions such as
inflammation and fibrosis (42, 46, 48, 65). Due to limited research investigating
alcohol-plus-toxicant effects, this study aimed to characterize metabolic impacts
that co-exposure would inflict. It is hypothesized that alcohol and PFOS will coindependently disrupt lipid, cholesterol, and xenobiotic metabolism.
Endogenous lipid synthesis pathways were shown to be primarily disturbed by
the decreased expression of various fatty acid and cholesterol related genes
(Figure 8). The Fasn gene encodes its protein that is involved in long chain fatty
acid synthesis in the presence of nicotinamide adenine dinucleotide phosphate
(NADPH). Fasn expression is typically disrupted in FLD models but was not
significantly altered due to PFOS or ethanol exposure. Fasn expression appears
to be elevated in the co-exposure group, but this observation was not statistically
significant. Scd-1 is another gene involved in fatty acid biosynthesis and is widely
known for its role in oleic acid synthesis. This model displayed an overall
decreased expression of Scd-1 due to ethanol consumption. Srebf1 and Srebf2
are important genes involved in regulating sterol synthesis and homeostasis that
encode respective proteins that bind the Sterol Response Element (SRE). Srebf1
and Srebf2 expression were primarily decreased in response to PFOS and
alcohol exposure. We however observed an interaction effect where Srebf1
expression was further decreased upon co-exposure to alcohol and PFOS.
27
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Next, it was of interest to look at various transporter genes involved in the
transport of fatty acids, sterols, and those proposed to be involved in PFAS
transport within the liver. The expression of several key transporters is found in
Figure 9. Cd36 and Fabp1 are major fatty acid transporter and translocation
genes that are typically investigated in FLD models due to their role in the
transportation of lipids between the liver and circulation. Cd36 expression was
increased in the presence of alcohol and PFOS, favoring lipid uptake into the
liver. Fapb1 expression was increased in pair-fed mice due to PFOS exposure
but was overall decreased due to ethanol consumption. Abcg5 and Abcg8 are
transporters involved in sterol secretion as bile from hepatocytes and into the bile
canaliculi. Both Abcg5 and Abcg8 expression were decreased in the ethanol-fed
mice. Finally, organic anion transporting proteins (OATP), or solute carrier
organic anion transporter (SLCO) were of interest to characterize because of
their proposed role in PFAS transport (66, 67). Slco1a1 and Slco1b2 both
exhibited a similar response to PFOS in pair-fed mice where their expression
was decreased. Both Slco1a1 and Slco1b2 expression were decreased in
ethanol-fed mice; however, an interesting interaction effect was prevalent in the
co-exposed group where expression was increased.
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Because the results thus far indicated possible perturbation of cholesterol
metabolism, it was of interest to examine Cyp7a1 expression (Figure 10).
Cyp7a1 is a conserved P450 enzyme and is known to act as the rate limiting step
in cholesterol metabolism to convert cholesterol to bile acids (68, 69). Cyp7a1
expression was shown to be increased with PFOS exposure, but predominately
decreased with ethanol consumption. Although, Cyp7a1 expression was reduced
in the ethanol-fed groups, a subtle induction in the co-exposure group was
evident, indicating a potential interaction effect. Cyp7a1 expression has
previously been shown to be downregulated in alcohol models and is suspected
to be a result of crosstalk between PPARα and LXR downregulation in response
to ethanol consumption (see Figure 12) (70, 71).
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Besides fatty acid synthesis disruption, it was also of interest to characterize
whether alcohol and PFOS influence fatty acid oxidation (Figure 11). Cpt1a and
Cpt2 are mitochondrial bound transferases that facilitate long-chain fatty acid
oxidation at the external (Cpt1a) and internal (Cpt2) mitochondrial membrane
(72). mRNA levels of Cpt1a and Cpt2 were suppressed in response to ethanol
consumption and there was a slight Cpt2 induction in response to PFOS
exposure. Cyp2e1 is a cytochrome P450 enzyme that is widely known for its role
in converting ethanol to its toxic intermediate, acetaldehyde, and the generation
of ROS. Previous studies have also demonstrated that Cyp2e1 induction is
involved in microsomal lipid peroxidation (73, 74). In the present study, Cyp2e1
expression was induced by PFOS exposure and displayed an interaction effect
that was not as prominent in pair-fed mice. Interestingly, high induction of
Cyp2e1 due to ethanol consumption was expected but was not observed. RTPCR analysis was also performed for ADH, the primary metabolizing enzyme of
ethanol, but there were no statistically significant differences between groups.
As shown in Figure 12, gene expression of nuclear receptor targets is shown.
Cyp4a10 and Cyp2b10 are genes also involved in fatty acid oxidation and their
function are discussed here. Cyp4a10 primarily functions to process lipids via ωhydroxylation and its expression was increased due to PFOS and ethanol
exposure. However, Cyp4a10 expression was not as abundant in the coexposure group, indicating a possible interaction effect. Also shown in Figure 12
is CAR target Cyp2b10 which is involved in xenobiotic and lipid homeostasis
(75). Cyp2b10 is generally expressed at low levels in murine livers but are highly
33

induced upon xenobiotic interaction with CAR (75, 76). This model demonstrated
a 6-fold response to PFOS in pair-fed mice and a 1500-fold response in the
ethanol-fed mice. When mice were co-exposed to ethanol and PFOS, Cyp2b10
was induced almost 500-fold indicating a dampened, interaction effect between
ethanol and PFOS.
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Validation of Nuclear Receptor Activation
Hepatic nuclear receptor activation was examined by RT-PCR of select target
genes to determine if PFOS inappropriately impacted metabolic pathways. One
of the most consistent findings in literature about PFAS mechanism of action is
the activation of PPARα; although, other studies are reporting that PFAS may
activate other nuclear receptors such as Constitutive Androstane Receptor
(CAR) and Liver X Receptor (LXR) (28, 77, 78). Nuclear receptor activation is
shown via target gene induction in Figure 12. PPARα expression was shown to
be suppressed due to ethanol exposure, which has been observed in previous
studies (79, 80). PPARα target gene Cyp4a10 was shown to be induced by
PFOS in pair-fed mice. PPARα activation was also observed in the co-exposure
group; however, not to the extent as the pair-fed mice, indicating a possible
interaction effect. Nuclear receptors CAR and LXR exhibited a similar
suppressive ethanol effect, where CAR expression was mildly induced in the coexposure group relative to ethanol-fed+vehicle. CAR target gene Cyp2b10 was
shown to be induced by PFOS in the pair-fed group but decreased induction in
the ethanol-fed group, indicating a possible PFOS and ethanol interaction.
Despite a possible interaction effect, Cyp2b10 was induced in the ethanol-fed
groups up to 1000-fold change. These findings indicate that CAR was activated
in response to ethanol consumption. LXR target gene Apob expression was
shown to be mildly downregulated in response to ethanol and more so upon coexposure to PFOS, further decreasing its expression. LXR target genes, Apob
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and Cyp7a1 were downregulated under ethanol’s influence indicating that LXR
was not activated or was suppressed due to ethanol’s presence.
Cyp4a10, Cyp2b10, and Apob expression were examined by RT-PCR to indicate
nuclear receptor activation but they are also key proteins involved in lipid
metabolism. Cyp4a10 is thought to play a role in ω-Hydroxylation of fatty acids
(31, 81). Cyp2b10 is a gene unique to mice (human analog Cyp2b6) and is
involved in xenobiotic metabolism (77, 82). Apob’s gene product is the primary
apolipoprotein of LDL and VLDL and assists with lipid export from the liver. HDL,
LDL, and VLDL were measured during serum analysis via Piccolo analysis.
These lipoproteins levels, however, were either not statistically significant or
displayed an ethanol only effect and are shown in relation to other results in
Figure 13. PFOS- and ethanol-related perturbations of these nuclear receptors
and their target genes indicate disruption of lipid and xenobiotic metabolism.
These observations may explain why there are opposing effects from ethanol
and PFOS. Thus far, this model has shown that ethanol primarily downregulates
and PFOS primarily upregulates targets genes and proteins involved in lipid
metabolism.
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CHAPTER IV
DISCUSSION AND CONCLUSIONS
Discussion
Exposures to environmental pollutants like PFOS have been associated with
adverse health effects such as elevated liver enzymes and dyslipidemia (21, 56).
In addition, the liver is also susceptible to insults by lifestyle factors including
poor diet and alcohol consumption (1). Environmental pollutants, like PFOS, are
ubiquitous and the growing prevalence of alcohol consumption has become
alarming. Therefore, it is important to consider multiple factors or the adoption of
a ‘multiple hit’ approach when characterizing disease endpoints to better
understand molecular mechanisms that drive pathological outcomes (11, 83).
This study sought to characterize the phenotype that an in vivo model would
develop after exposure to PFOS while consuming an ethanol diet. The
development of ‘multiple hit’ approaches are especially important to the growing
field of environmental and liver toxicology to gain a holistic understanding of what
human’s encounter. To our knowledge, no models have been developed that
investigate the impact of co-exposures to environmental pollutants and alcohol
consumption. In the present study, we developed a toxicant-plus-alcohol mouse
model and evaluated fatty liver disease endpoints including steatosis, injury and
inflammation, energy and xenobiotic metabolism disruption, and nuclear receptor
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activation. Our results demonstrated that male C57BL/6 mice that were exposed
to PFOS via oral gavage, while consuming a 5% ethanol diet, developed hepatic
steatosis accompanied with hepatic metabolic disruption. A graphical
representation of our summarized observations is shown in Figure 13.
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The first observation we made during model development included body weight
gain and diet intake. Body weight recordings are an imperative aspect of rodent
alcohol models as they are indicators of health. According to the widely used
NIAAA model, mice frequently suffer from weight loss as they adjust to the
alcohol diet and may experience hypothermia, resulting in increased mortality
(40). While developing this novel alcohol-plus-toxicant model, we used the
NIAAA model as a foundation and administered PFOS by oral gavage. Oral
gavage is known to be a stressful event for mice, and we postulate that the
repeated stress from daily oral gavage contributed to weight loss over the course
of study which plateaued after about a week (Figure 2). This weight loss was
prolonged in mice in the ethanol-fed group and may be due to the combination of
adapting to 5% ethanol consumption and the daily oral gavage procedure. Future
studies will be designed so that the potential combinatorial stress events are
negated by performing biweekly gavage.
Monitoring diet consumption is also critical in alcohol models to maintain an
isocaloric intake between control (pair-fed) and experimental (ethanol-fed)
groups. Diet intake was recorded daily for each cage over the period of the study
and displayed a similar pattern to body weight recordings (Figure 2). Diet intake
steadily decreased over the first two weeks and plateaued for the remainder of
the study. Although, it should be mentioned that these values do not reflect the
consumption per mouse, rather, they reflect the mean diet consumed in each
group (n=10) per day of the study. Therefore, certain factors need to be
accounted for while viewing Figure 2, such as i) the presence of dominant
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animals in a single cage that consume more than others ii) when mice were
prematurely euthanized due to weight loss iii) if the alcohol feeding resulted in
lethal toxicity, which is typical in a chronic-binge model (40).
Post-euthanasia, we performed extensive hepatic characterization to assess FLD
endpoints including steatosis, inflammation, and injury. The primary endpoint of
this study was to characterize the potential interaction effect of ethanol and
PFOS to induce fatty liver. Hepatic steatosis is one of the first defining
phenotypic features during the development of fatty liver diseases (84). In the
present study, hepatic steatosis was examined by liver-to-body weight ratio, H&E
staining, and quantification of hepatic triglycerides and cholesterol (Figures 3-5).
We observed an increase of liver-to-body weight ratio, primarily in the ethanol
consuming mice. Livers were found to weigh even more in the co-exposure
group. We also calculated adipose-to-body weight ratio and found that these
values were not significantly different from controls. This suggests that there
potentially are more lipids being deposited in the liver and not necessary into
adipose for long-term energy storage. This observation is also supported by the
increased expression of Cd36, a lipid importer, and decreased expression of
Apob, a lipid exporter.
When comparing H&E-stained sections, we not only see higher lipid droplet
formation in the ethanol-fed+PFOS exposed group, but an interesting zonal
pattern beginning to form. Lipid droplets seem to form a trail between zone 2 to
zone 1 of the liver acinus or near the periportal area in the ethanol-fed+PFOS
group (Figure 4). The ethanol-fed+vehicle and pair-fed+vehicle groups appeared
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to form lipid droplet patterns around zone 3 to zone 2 or more near the
pericentral area of the liver acinus. Steatosis typically begins in zone 3 and
‘migrates’ outward towards the periportal space with increasing steatotic severity
(85). However, here we observed little to no lipid droplet formation in zone 3 and
an accumulation more near zone 2 to zone 1. We performed Masson’s Trichrome
staining for fibrosis, but no obvious fibrotic lesions were present (not shown).
This observation may be the result of metabolic disruption of microenvironments
that exist between the portal vein and central vein where there is an inverse
gradient of oxygen tension and metabolism (86).
Elevated plasma ALT and AST are expected outcomes from the chronic-binge
NIAAA alcohol diet (40, 62). The ‘binge’ component of this model was specifically
incorporated into the design to study how acute, high-dose ethanol consumption
can negatively impact the liver by releasing these aminotransferases into
circulation. We did not observe any obvious PFOS impact on ALT and AST
measurements (Figure 5); although, high serum levels of PFOS and PFOA have
been associated with elevated ALT in heavily exposed residential populations
(87, 88). Here, we specifically used a lower concentration of PFOS to reflect
average human exposure rather occupationally exposed individuals or those who
live near PFAS manufacturing plants.
Previous PFAS research examining immunotoxicity has had conflicting results
and may vary based on model design, dose, and what PFAS congener is used.
Published literature suggests that PFAS compounds largely suppress antibody
responses and can suppress or induce cytokine release (89). We observed an
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elevation of IL-6 expression and plasma protein levels (Figure 7). Some
literature suggests that the induction of IL-6 in response to PFOS exposure may
be from stimulated B cells (51). Others report an increased amount of IL-6
production in response to PFOS exposure ex vivo from macrophages (90).
Further investigation is required to understand the immunotoxic effects imposed
by PFAS compounds. Ethanol consumption is regarded as pro-inflammatory due
to the generation of toxic intermediates, ROS, and activation of innate immune
cells. There is also growing research that indicates that the gut-derived microbial
release of lipopolysaccharide (LPS) can also initiate inflammation (91). Previous
research suggests that IL-6 is a protective response against ethanol-induced
ROS (92). The increase of IL-6 expression and protein abundance could
potentially be an immune-protective effect; however further investigation is
required to understand this effect.
Together, these analyses indicate increased accumulation of hepatic lipids in
response to alcohol consumption and PFOS exposure. Furthermore, a minor
inflammatory response and elevated ALT and AST were observed, primarily due
to ethanol consumption. No obvious interaction effect was observed in these
figures, but it may be possible that ethanol and PFOS work independently to
result in FLD. Alcohol consumption and PFOS exposure similarly promote lipid
accumulation in hepatocytes by increasing fatty acid uptake and decreasing lipid
oxidation (25, 57, 93). We also observed a decrease in de novo lipogenesis. This
may be a compensatory response or because lipid sensors like PPARα or
SREBP’s ‘detect’ ethanol or PFOS presence (which structurally resemble fatty
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acids) to shut down lipid synthesis. To discriminate differential modifications from
ethanol or PFOS on FLD progression, we must dissect differences imposed on
energy and xenobiotic metabolism.
Metabolic disruption is a common endpoint that investigators examine for liverrelated toxicant and alcohol research. Previous research has indicated that both
ethanol and PFOS are capable of modulating energy metabolism which
contributes to FLD progression. Here, we examined the expression of key genes
involved in lipid and cholesterol metabolism. Specifically, we evaluated the
expression of genes involved in synthesis, transport, and oxidation of lipids.
Several of these genes are regulated by multiple nuclear receptors
simultaneously discussed previously (29, 94, 95).
Expression of lipid synthesis genes Scd-1, Srebf1, and Srebf2 were observed to
be decreased in response to both ethanol and PFOS exposure, independently
(Figure 8). Curiously, most published literature indicate that alcohol consumption
upregulates lipogenesis and downregulates fatty acid oxidation (57, 96). A
possibility for why lipid synthesis was decreased in our ethanol-fed mice may be
a result of impacted transporters. Expression of lipid importer Cd36 was
upregulated in response to alcohol while expression of lipid exporters like Abcg5,
Abcg8, and ApoB were downregulated. This occurrence could result in the total
net increase of liver-to-body weight, lipid droplet formation, and hepatic
triglycerides (Figure 3-5).
Transporters are a critical component of this model due to their mediation of the
import of fatty acids and potentially PFAS themselves into hepatocytes. We
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examined the expression of Cd36 and Fabp1, which are known lipid transporters
in the liver. Cd36 expression was upregulated in response to ethanol and PFOS
exposure in ethanol-fed mice; whereas Fabp1 expression was increased in pairfed mice but decreased in ethanol-fed mice (Figure 9). Previous alcohol studies
have shown that Cd36 is upregulated and contributes to hepatic steatosis (97,
98). NAFLD models studying PFOS effects have found that Cd36 expression is
increased to handle excess fat and PFAS may be doing so by structurally
mimicking long-chain fatty acids (93, 99). Contradictory to our results, Huck, I. et
al found that mice consuming a high fat diet while exposed to PFOS exhibited a
decrease of Cd36 expression (100). On the other hand, we show that Fabp1 was
decreased in ethanol-fed mice and increased in pair-fed mice in response to
PFOS exposure. Various studies using rodent NAFLD and ALD models have
shown that Fabp1 expression is decreased (101-103). It is unclear how PFOS
may influence Fabp1 expression, but it could be due to structural similarities
between PFOS and fatty acids.
It is also of interest to characterize how ethanol and PFOS exposure influence
cholesterol and bile acid transport due to their known impact on each (59, 104).
In the present study, we examined the expression of Abcg5 and Abcg8, two
transporters that heterodimerize to facilitate the export of bile acids from the
hepatocyte and into the bile canaliculus (105). We found that PFOS did not
influence these transporters, but they were downregulated in response to ethanol
consumption (Figure 9). This observation is consistent with our results where
ethanol-fed mice had less hepatic cholesterol and sterol synthesis genes were
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downregulated (Figure 5, 8). Future studies must consider measuring hepatic
and serum bile acids to test if their levels are decreased following ethanol
consumption, which could impact intestinal excretion.
Recent reports have found that organic anion transporting polypeptides (OATP),
or solute carrier organic anion transporter (SLCO) may play a role in the hepatic
uptake of PFAS (102). Pfohl, M. et al states that a high fat diet may contribute to
the decreased uptake of PFAS into the liver where they demonstrate a
decreased expression in high fat consuming mice for Slco1a1 (Oatp1a1) and
Slco1b2 (Oatp1b2). PPARα activation by PFAS has shown to downregulate
these transporters (66). In this model, ethanol consumption significantly reduced
the expression of Slco1a1 and Slco1b2 (Figure 9). The Lieber-DeCarli control
and ethanol diet are considered high fat diets and here the expression of these
transporters was decreased. This model therefore may result in less PFOS
accumulation in the liver and less hepatic damage imposed by PFOS-related
stress. Future studies must incorporate analysis of hepatic and serum PFAS
measurements to understand their distribution in various model as diet and
exposure can influence their uptake.
Finally, we assessed lipid catabolism genes and how their expression is
impacted by alcohol and PFOS exposure. Overall, lipid oxidation was found to be
decreased in response to ethanol consumption and increased due to PFAS
exposure (Figure 11). Our gene expression data indicates that mitochondrial
oxidation was decreased while cytochrome P450 oxidation was increased
(Figure 11, 12). Mitochondrial oxidation is more robust and is primarily under the
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control of PPARα. If mitochondrial oxidation is lost, hepatocytes may utilize other
mechanisms of lipid oxidation, such as cytochrome oxidation, which were found
to be upregulated in this model (99). Due to the roughly 3-fold decreased
expression of PPARα in the ethanol-fed mice, lipid oxidative pathways were
disrupted, possibly resulting in the net accumulation of lipids in hepatocytes.
Nuclear receptors and subsequent signaling that may be influenced by either
ethanol or PFOS are central to this developing model. By understanding their
role in regulating a vast number of metabolic processes, we can begin to
understand potential interactions between PFOS and ethanol to influence FLD
progression and metabolic disturbances. Various PFAS have shown to activate
other nuclear receptors including PPARα and CAR, but not all PFAS activate
them equally (82, 106).
PPARα is known as a transcriptional lipid sensor to respond to dietary lipids and
essential metabolites to regulate lipid and cholesterol metabolism (107). PFAS
structurally resemble fatty acids and are capable of inappropriately activating
PPARα and bind various transporters such as FABP1 and albumin (108-110). In
the present study, PFOS demonstrated a modest capability to activate PPARα
(Figure 12) indicating that lipid homeostasis was altered. Ethanol consuming
mice however, demonstrated a suppression of PPARα and potentially resulted in
masking the expression of its targets: Cyp4a10, Cpt1a, Cpt2, Scd-1 (Figures 8,
11, 12). This implies that ethanol also disrupted lipid homeostasis resulting in
hepatic steatosis and disrupted metabolism.
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Recently, PFAS ability to activate CAR have gained attention as CAR is regarded
as a master xenobiotic metabolism regulator and has shown to crosstalk with
PPARα (29, 95). We observed CAR activation via target gene Cyp2b10 induction
by PFOS in pair-fed mice and a robust response in ethanol consuming mice
(Figure 12). Previous studies have illustrated that CAR may play a protective
role in ALD and NAFLD rodent models (111, 112). PPARα activation has also
been extensively investigated for its potential protective role in FLD models (79,
113, 114). In fact, PPAR activation has been a proposed therapeutic target to
treat NAFLD; however, human studies have been inconsistent or have not been
successful (115). Another proposal has been made suggesting that PPARα
agonists may be a useful therapy for treating ALD (116). Here, we demonstrate
that PFOS activates PPARα, which may have acted as a protective mechanism
against alcohol-related pathology.
Finally, it was of interest to examine LXR activation due to its known role in lipid
and sterol metabolism. Like PPARα and CAR, LXR expression was suppressed
due to ethanol consumption in murine livers (Figure 12). LXR’s target gene of
interest, Cyp7a1, expression was dramatically suppressed due to ethanol,
suggesting cholesterol catabolism was negatively affected. LXR and PPARα both
heterodimerize with RXRα during transcription and may compete with one
another to favor lipid synthesis or degradation, respectively, dependent on the
ligand (70).
Here, we demonstrate ethanol and PFOS ability to impact nuclear receptor
signaling. PPARα, CAR, and LXR share transcriptional targets and have shown
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to crosstalk with one another to influence lipid metabolism (70, 117). In this
model, ethanol seemingly dominated and suppressed nuclear receptor activity,
whereas PFOS subtly activated transcriptional targets in pair-fed mice only. More
work will need to be done to understand nuclear receptor crosstalk and this
model’s influence on the liver’s complex regulatory metabolism system.
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Conclusions
In the present study, we describe how ethanol consumption and PFOS exposure
may interact to induce fatty liver with comorbid metabolic disruption. This concept
was demonstrated by modifying the widely used NIAAA chronic-binge alcohol
rodent model by exposing mice to PFOS by oral gavage. The observations in this
study will be used as a foundation for a developing co-exposure or two-hit model
that seeks to explain toxicant modification of alcohol-induced liver injury.
Ultimately, this study serves as a pilot investigation to develop a generalized
alcohol-plus-toxicant model to explore various toxicant interactions with ethanol
consumption, a lifestyle factor.
We observed that mice co-exposed to ethanol and PFOS induced hepatic
steatosis which is reflected by an accumulation of lipids in the liver and increased
liver weight. Liver injury and inflammation was indicated by elevated serum ALT,
AST, and IL-6. Hepatic IL-6 expression was induced due to ethanol and PFOS
co-exposure. We further characterized our findings by investigating lipid
metabolism via gene expression analysis for the induction of synthesis, transport,
and oxidation related genes. We found that lipid synthesis, transport, and
mitochondrial oxidation were suppressed, while lipid uptake and alternative lipid
oxidation enzymes, cytochrome P450’s, were elevated. Nuclear receptors
PPARα, CAR, and LXR were influenced by ethanol and PFOS and were largely
found to be suppressed by ethanol and induced by PFOS exposure. Subsequent
metabolic regulation by these nuclear receptors then influenced lipid and
cholesterol metabolism. Alcohol effects seemingly dominated in this model with
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subtle PFOS effects. This is potentially due several occurrences i) the
introduction of PFOS after the ethanol diet was established ii) ethanol
suppressed nuclear receptor expression which would impact downstream targets
iii) ethanol suppression of various transporters.
Our conclusions may be limited due to lethal toxicity observed during the study.
For example, blood chemistry analysis of the co-exposure group had an n equal
to 3 for ALT, AST, and other measurements that were not shown. We believe this
group’s total n was affected due to the combined exposure to ethanol feeding
and PFOS oral gavage. This observation can be negated in future studies by
altering the frequency of oral gavage while maintaining the total exposure
administered over the duration of the study. Biweekly oral gavage is one method
we will consider incorporating in this model to ensure mice are not under
considerable stress each day of the study. The route of exposure may also be
changed to solubilizing PFOS directly in the water that will then be used to make
up the Lieber-DeCarli alcohol diet. Schlezinger J. et al demonstrated that PFOA
can be solubilized in highly pure water with sucrose by simply mixing the solution
for several hours or overnight (29). Another limitation in our approach that will be
accounted for in future studies is quantification of hepatic and serum PFOS
levels. Detection methodology of PFAS in human and rodent models are being
developed by the EPA (Method 537 Modified) and other researchers (23, 118,
119). Integration of Liquid Chromatography Tandem Mass Spectrometry (LCMS/MS) analysis to this model will be imperative to ensure that PFAS are
reaching the liver despite the influence of ethanol exposure. Our observation that
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ethanol negatively impacts transporters that facilitate hepatic PFAS import was
not known during model design. This model is being developed to understand
potential alcohol and toxicant interactions, so it is critical to ensure that the
toxicant of interest can enter hepatocytes to study their effects.
Future studies will utilize knockout or humanized mouse models and ‘Omics
approaches to dissect complex energy regulatory mechanisms that are disrupted
due to ethanol and/or PFOS exposure. Because this is a developing model, we
eventually aim to use other pollutants including various volatile organic
compounds (VOCs) or POPs. These compounds have previously shown to
impact the liver and this approach can help to better understand disease
progression and identify populations that may be at risk. Some other design
parameters that can be modified include the duration of exposures, sequence of
exposure, and increasing our total N. The conclusions made from the present
study will be helpful moving forward to further refine the model and is an
indication of what pathways and regulatory mechanisms that are disturbed under
alcohol and toxicant exposure.
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APPENDIX I
Gene of Interest name
Peroxisomal Proliferator Receptoralpha
Cytochrome P450 family 4, subfamily
a, polypeptide 10
Constitutively activated Androstane
Receptor
Cytochrome P450 family 2, subfamily
b, polypeptide 10
Liver X Receptor
Apolipoprotein B
Fatty Acid Synthase
Stearoyl-CoA Desaturase 1
Sterol Regulatory Element Binding
Transcription Factor 1
Sterol Regulatory Element Binding
Transcription Factor 2
Cluster Differentiation 36 (Fatty Acid
Translocase)
Fatty Acid Binding Protein
ATP Binding Cassette Subfamily G
Member 5
ATP Binding Cassette Subfamily G
Member 8
Solute carrier organic anion
transporter family member 1a1
Solute carrier organic anion
transporter family member 1b2
Alcohol Dehydrogenase
Cytochrome P450 family 7, subfamily
a, polypeptide 1
Carnitine Palmitoyltransferase 1a
Carnitine Palmitoyltransferase 2
Cytochrome P450 family 2, subfamily
e, polypeptide 1
Interleukin 6

Abbreviated
name
PPARα

Mm00440939

Cyp4a10

Mm02601690

CAR (Nr1i3)

Mm01283978

Cyp2b10

Mm01972453

LXR (Nr1h3)
Apob
Fasn
Scd-1
Srebf1

Mm00443451
Mm01545150
Mm00662319
Mm00772290
Mm00550338

Srebf2

Mm01306292

Cd36

Mm00432403

Fabp1
Abcg5

Mm00443440
Mm00446241

Abcg8

Mm00445970

Slco1a1

Mm01267415

Slco1b2

Mm00451510

ADH
Cyp7a1

Mm00507711
Mm00484150

Cpt1a
Cpt2
Cyp2e1

Mm01231183
Mm00487205
Mm00491127

IL-6

Mm00446190
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